Genmab A/S (NASDAQ:GMAB) Price Target Raised to $52.00

Genmab A/S (NASDAQ:GMAB) had its price target lifted by TD Cowen from $43.00 to $52.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also issued reports on GMAB. New Street Research set a $43.00 target price on Genmab A/S in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. HC Wainwright upped their price target on Genmab A/S from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Truist Financial upped their price target on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Finally, Guggenheim raised their price objective on Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.39.

Genmab A/S Price Performance

GMAB stock opened at $57.29 on Monday. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97. The company has a market cap of $35.75 billion, a P/E ratio of 45.11, a PEG ratio of 2.01 and a beta of 0.81. The firm has a 50-day moving average of $36.20 and a 200 day moving average of $30.36. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, sell-side analysts forecast that Genmab A/S will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its stake in Genmab A/S by 46.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,692 shares of the company’s stock worth $629,000 after purchasing an additional 5,615 shares in the last quarter. Park Avenue Securities LLC grew its position in Genmab A/S by 2.4% during the 3rd quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock valued at $402,000 after purchasing an additional 265 shares during the last quarter. Signaturefd LLC grew its position in Genmab A/S by 8.5% during the 3rd quarter. Signaturefd LLC now owns 17,842 shares of the company’s stock valued at $636,000 after purchasing an additional 1,400 shares during the last quarter. Quadrant Capital Group LLC increased its stake in Genmab A/S by 3.5% during the 3rd quarter. Quadrant Capital Group LLC now owns 23,243 shares of the company’s stock valued at $850,000 after purchasing an additional 786 shares in the last quarter. Finally, Capital Square LLC bought a new stake in Genmab A/S during the 3rd quarter valued at about $219,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that the Phase 3 LiGeR-HN1 trial met both primary endpoints in first-line, PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. Petosemtamab combined with Merck’s pembrolizumab reduced the risk of death by 50% versus pembrolizumab alone, with a statistically significant improvement in overall survival and objective response rate, regardless of patients’ HPV status. Genmab Phase 3 trial announcement
• Positive Sentiment: The results support expectations that petosemtamab could become a meaningful commercial product and potentially establish a new treatment standard. Analysts described the results as a significant “hat trick,” while reports highlighted the drug’s potential in combination with Keytruda. Barron’s report on Genmab’s record high
• Positive Sentiment: JPMorgan upgraded its rating on GMAB, and TD Cowen said the stock could rise, adding to the positive analyst sentiment. Heavy call-option activity also indicates strong speculative interest following the clinical announcement. JPMorgan rating upgrade
• Neutral Sentiment: Genmab plans to discuss the results with global regulators and submit the full dataset for presentation at a future medical meeting. Investors still lack the complete efficacy and safety details, and regulatory approval and commercialization remain ahead. Genmab Phase III data discussion

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.